Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Luis A. Díaz, Kai‐Keen Shiu, Tae‐Won Kim, +16

The Lancet Oncology

MedicineImmunologyPathologyColorectal CancerPembrolizumab Versus Chemotherapy +7

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.

Thierry André, Kai‐Keen Shiu, Tae Won Kim, +17

Journal of Clinical Oncology

ImmunologyPathologyLba4 BackgroundKeynote-177 StudyOncology +14

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Thierry André, Elena Élez, Eric Van Cutsem, +24

New England Journal of Medicine

Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.

Luis A. Díaz, Aurélien Marabelle, Jean‐Pierre Delord, +16

Journal of Clinical Oncology

Msi-h CancerMedicineMicrosatellite InstabilityImmunologyTumor Immunity +11

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

Thierry André, Elena Élez, Heinz‐Josef Lenz, +26

The Lancet

MedicineColorectal CancerPathologyImmune Checkpoint InhibitorIpilimumab Versus Nivolumab +4

ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i>^V600E-Mutant Metastatic Colorectal Cancer

Eric Van Cutsem, Rona Yaeger, Takayuki Yoshino, +15

Journal of Clinical Oncology

Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164

Dung T. Le, Luis A. Díaz, Tae Won Kim, +17

European Journal of Cancer

Microsatellite Instability–high/mismatch Repair–deficientMedicineImmunologyColorectal CancerPathology +7

Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

Thierry André, Kai‐Keen Shiu, Tae Won Kim, +17

Journal of Clinical Oncology

Cancer ManagementImmunologyPathologyPharmacotherapyOncology +18

Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers

Luis A. Díaz, Aurélien Marabelle, T.W. Kim, +17

Annals of Oncology

OncologyKeynote-158 StudiesMedicineImmunologyPathology +6

KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer.

Kai‐Keen Shiu, Thierry André, Tae Won Kim, +17

Journal of Clinical Oncology

ImmunologyPathologyOncologyGastrointestinal OncologyMetronomic Therapy +14